XtalPi Sets 2026 AGM to Seek Shareholder Mandates on Buy-backs and New Issues

QuantumPharm, Inc. ( (HK:2228) ) has shared an announcement.

XtalPi Holdings Limited has called its annual general meeting for 20 May 2026 in Shenzhen, where shareholders will review the audited consolidated financial statements for the year ended 31 December 2025 and receive reports from the board and the external auditor. The meeting will also consider the re-election of executive and independent non-executive directors, the renewal of PricewaterhouseCoopers as auditor, and the granting of mandates that would allow the board to repurchase up to 10% of the company’s issued shares and to issue additional equity or convertible securities in line with Hong Kong listing rules, potentially giving management greater flexibility in capital management and corporate finance activities.

These proposed mandates, if approved, would equip XtalPi with tools to adjust its capital structure through buy-backs and new issuance without seeking separate shareholder approval for each transaction within the defined period. Such authorizations are common among Hong Kong-listed issuers and can influence liquidity, ownership structure, and the company’s capacity to respond swiftly to market conditions or strategic opportunities, with implications for existing shareholders and prospective investors.

More about QuantumPharm, Inc.

XtalPi Holdings Limited is a Cayman Islands incorporated company listed in Hong Kong and focused on technology-enabled solutions, with operations including facilities in Shenzhen’s International Biomedical Industrial Park. The company is overseen by a board comprising executive and independent non-executive directors and engages a major international audit firm for its financial reporting and compliance needs.

Average Trading Volume: 56,007,390

Technical Sentiment Signal: Buy

Current Market Cap: HK$43.57B

For an in-depth examination of 2228 stock, go to TipRanks’ Overview page.